NASDAQ: SXTP60 Degrees Pharmaceuticals Inc Stock
$2.21-0.07 (-3.07%)
Updated Jun 13, 2025
SXTP Price
$2.21
Fair Value Price
N/A
Market Cap
$3.26M
52 Week Low
$1.41
52 Week High
$35.99
P/E
-0.09x
P/B
0.79x
P/S
3.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$718.26k
Earnings
-$10.25M
Gross Margin
42.6%
Operating Margin
-1,426.44%
Profit Margin
-1,495.8%
Debt to Equity
0.47
Operating Cash Flow
-$6M
Beta
-0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SXTP Overview
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SXTP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SXTP
Ranked#236 of 464
Ranked#236 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important SXTP news, forecast changes, insider trades & much more!
SXTP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SXTP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SXTP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SXTP is good value based on its book value relative to its share price (0.79x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
SXTP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SXTP due diligence checks available for Premium users.
Valuation
SXTP fair value
Fair Value of SXTP stock based on Discounted Cash Flow (DCF)
Price
$2.21
Fair Value
-$3.03
Undervalued by
172.89%
SXTP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SXTP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
-108.97x
Market
31.36x
SXTP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.79x
Industry
4.66x
SXTP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SXTP's financial health
Profit margin
Revenue
$183.0k
Net Income
-$1.9M
Profit Margin
-1,095.4%
SXTP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SXTP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.0M
Liabilities
$1.9M
Debt to equity
0.47
SXTP's short-term assets ($5.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SXTP's short-term assets ($5.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SXTP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$1.7M
Financing
$1.7M
SXTP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SXTP vs Biotech Stocks
60 Degrees Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.